Mystic Miller’s review of ’22 and predictions for ’23

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with independent life sciences consultant Jim Miller. Your host, Raman Sehgal sits down with Jim covering:

• The three biggest macro factors impacting the CDMO space right now
• How CDMOs and CROs are starting to feel the pain of emerging biotech’s funding woes
• What we can learn from the 08-09 financial crash that can help CDMOs/CROs during rockier financial times
• The cooling of M&A and company valuations, and why financial stability may become a more important selection criteria
• Where Jim would place his attention and money if he was running a CDMO...

Jim Miller is a renowned expert in the space and a regular speaker at all the major trade conferences including CPhI WW. He made his name in the sector after founding and growing PharmSource with his wife Judy, an online database on bio/pharmaceutical intelligence, before selling the business to Global Data. Today, he’s an industry consultant and regularly writes for leading industry publications like DCAT and Pharmaceutical Technology.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.